A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infection

Trial Profile

A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Danoprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ATLAS
  • Sponsors Roche
  • Most Recent Events

    • 22 Apr 2012 Final results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.
    • 24 Mar 2012 Planned number of patients changed from 240 to 300 as reported by European Clinical Trials Database.
    • 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top